Therapeutic Asset Ratings
13,155 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Abemaciclib
Metastatic Prostate Carcinoma
Praful Ravi, MB BCHir, MRCP
P2
B
(59)
Abemaciclib
Triple-Negative Breast Carcinoma
UNC Lineberger Comprehensive Cancer Center
P2
B
(59)
Adavosertib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)
P2
B
(59)
Adriamycin
Colorectal Neoplasm
Eisai Inc.
P2
B
(59)
Adriamycin
Refractory Malignant Neoplasm
BeOne Medicines
P2
B
(59)
Alirocumab
Cerebral Atherosclerosis
Chang Gung Memorial Hospital
P2
B
(59)
Alpelisib
Ovarian Carcinoma
National Cancer Institute (NCI)
P2
B
(59)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Myelodysplastic Syndrome With Excess Blasts
M.D. Anderson Cancer Center
P2
B
(59)
Astarabine
Acute Myeloid Leukemia
BioSight Ltd.
P2
B
(59)
Atezolizumab
Biliary Tract Cancer
Replimune, Inc.
P2
B
(59)
Atezolizumab
Head And Neck Cancer
Centre Georges Francois Leclerc
P2
B
(59)
Atezolizumab
Non-Hodgkin Lymphoma
Genentech, Inc.
P2
B
(59)
Atezolizumab
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
P2
B
(59)
Atezolizumab
Sarcoma
Cancer Research UK
P2
B
(59)
Avutometinib
Lung Cancer
Emory University
P2
B
(59)
Azacitidine
Mixed Phenotype Acute Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
P2
B
(59)
Azacytidine
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center
P2
B
(59)
Azeliragon
Glioblastoma
Washington University School of Medicine
P2
B
(59)
Balstilimab
Malignant Pancreatic Neoplasm
Nelum Corp
P2
B
(59)
Bendamustine
B-Cell Non-Hodgkin Lymphoma
Swiss Cancer Institute
P2
B
(59)
Bendamustine
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
B
(59)
Bet Bromodomain Inhibitor Zen-3694
Metastatic Prostate Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P2
B
(59)
Binimetinib
Refractory Malignant Neoplasm
N.N. Petrov National Medical Research Center of Oncology
P2
B
(59)
Boserolimab
Non-Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
P2
B
(59)
Cabozantinib
Metastatic Melanoma
National Cancer Institute (NCI)
P2
B
(59)
Showing 2276 to 2300 of 13,155 assets
Previous
Page 92 of 527
Next